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This document describes best practice and evidence based recommendations for the use of FDG-PET/CT
for the purposes of radiotherapy target volume delineation (TVD) for curative intent treatment of non-
small cell lung cancer (NSCLC). These recommendations have been written by an expert advisory group,
convened by the International Atomic Energy Agency (IAEA) to facilitate a Coordinated Research Project
(CRP) aiming to improve the applications of PET based radiation treatment planning (RTP) in low and
middle income countries. These guidelines can be applied in routine clinical practice of radiotherapy
TVD, for NSCLC patients treated with concurrent chemoradiation or radiotherapy alone, where FDG is
used, and where a calibrated PET camera system equipped for RTP patient positioning is available.
Recommendations are provided for PET and CT image visualization and interpretation, and for tumor
delineation using planning CT with and without breathing motion compensation.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 116 (2015) 27–34 This
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4.0/).18F-ﬂuorodeoxyglucose (FDG) positron emission tomography
(PET) is recommended as a useful tool in helping staging accuracy
and treatment planning [1]. FDG-PET is superior to computed
tomography (CT) alone in the staging of lung cancer [2,3]. It is
now considered a routine investigation in the baseline staging
evaluation of patients with non-small cell lung carcinoma
(NSCLC) who are being considered for radical intent treatment
[4]. When PET is acquired in conjunction with a CT (PET/CT), the
combined PET/CT information has been shown to have greaterstaging accuracy than PET imaging alone [5–10]. A combined
PET/CT acquisition is now the standard method of acquiring
FDG-PET images for the purposes of baseline staging and for radio-
therapy treatment planning (RTP) [1].
The introduction of FDG-PET has been shown to have a signiﬁ-
cant impact in selecting patients for curative intent or ‘‘radical’’
radiotherapy [11–14]. PET imaging also has been noted to reduce
inter-observer variation when used to guide target volume delin-
eation in RTP in NSCLC patients [15–18]. Furthermore the acquisi-
tion of a dedicated PET/CT scan for the purposes of RTP in patients
who have had a previous staging PET/CT has been shown to have
further impact in reducing inter-observer variation [19].
A number of techniques have been used to generate RTP target
volumes using the information gleaned from PET and CT. Most
clinical studies have used a visual interpretation technique, while
others have reported the use of automated segmentation tech-
niques to either guide or generate the relevant target volume
[1,20–23]. A previous International Atomic Energy Agency (IAEA)
publication provided guidance on the use and role of PET/CT
imaging for RTP in a range of tumor sites [24].
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Following an IAEA Expert Meeting on the use of PET/CT imaging
for RTP in Vienna in July 2013 it was decided to update the pre-
vious IAEA report to provide clear guidance on target volume delin-
eation (TVD) using PET/CT imaging, speciﬁcally for the applications
in lung cancer and taking advantage of the considerable research
activity that has occurred since the last reports. This publication
focuses entirely on the use of FDG-PET/CT in deﬁning the target
for RTP in NSCLC and seeks to update the previous guidance in light
of emerging evidence and consensus opinion.
To ensure the inclusion of relevant publications the following
search was undertaken. The terms ‘‘positron emission tomogra-
phy’’, ‘‘Non-Small Cell Lung Cancer’’, ‘‘target volume delineation’’
and ‘‘Radiotherapy’’, along with their derivatives were used to
search PubMed. All studies relating to PET/CT for target volume
delineation in the treatment of NSCLC with radiotherapy and of
relevance to this overview were included in the preparation
of the review. No limitations were placed on language or year of
publication.Background of PET based radiotherapy target volume
delineation in NSCLC
The ﬁrst human PET scanner was constructed in 1974, but it is
only in the last 16 years that clinical studies have examined the
impact of using FDG-PET for TVD in NSCLC [25,26]. Early studies
simply described the impact on the treatment volume, often with-
out any quantiﬁcation [26]. Several staging studies clearly demon-
strated the superiority of PET/CT over CT for identiﬁcation of
involved mediastinal lymph nodes [27,28]. PET based TVD was also
shown to improve the inclusion of truly involved mediastinal
lymph nodes [29]. In patients with atelectasis, it was apparent
from the earliest studies that PET could help discriminate collapsed
lung from tumor [30]. This approach is now widely accepted and
clinically applied, although few studies have undertaken a direct
validation of imaging against pathological specimens due to the
difﬁculties with correlation and processing artefacts [31–33]. A
number of studies have sought to measure the impact of FDG-
PET/CT based TVD on inter-observer variation or against a ‘gold
standard’. Besides the impact on staging, FDG-PET/CT imaging
greatly reduces the undesirable impact of inter-observer variation
[19]. In addition, PET/CT based target volume delineations are on
average smaller than their non-PET counterpoints, thereby reduc-
ing the dose to normal structures. This may open the possibility
of dose escalation [34,35].Acquiring a PET/CT scan for the purposes of target volume
delineation
FDG-PET/CT imaging for the purposes of baseline staging is now
considered as ‘standard of care’ in patients with NSCLC being con-
sidered for treatment with radical intent [4]. Hence any patient
considered for radical radiotherapy should have had a staging
PET/CT. When used in its most basic form, without speciﬁc adapta-
tions for RTP, images from a staging PET/CT scan can be visually
correlated with the RTP CT to identify areas of disease for inclusion
within the treatment volume. The accuracy of correlating a staging
PET/CT scan and a planning CT will be improved by fusing both
image sets. However, most staging scans are acquired on a curved
top couch, possibly with the patient’s arms positioned down by
their side, while an RTP CT is usually acquired on a ﬂat top CT
couch with arms immobilized above the patient’s head. The result-
ing differences in position between the two scans may make
anatomical registration of these image sets difﬁcult, leading tointerpretation issues and potential inaccuracies in TVD.
Therefore, these images should not be coregistered in a treatment
planning system for the purpose of tumor delineation. Deformable
registration has been used in an effort to account for differences in
patient positioning between imaging studies acquired in different
positions. However, elastic registration is difﬁcult due to the differ-
ences in acquisition technique between PET and CT, and deforma-
tion of PET images would compromise their inherently good
representation of average tumor positions in case of breathing
motion. The use of deformable registration to combine a diagnostic
PET/CT scan with an RTP CT scan has not been consistently vali-
dated and at present is not recommended for this purpose [36].
In conclusion, there are no validated strategies available that
would allow the use of a diagnostic PET/CT for reliable image
fusion with an RTP CT.
Technically the best available option is to acquire a PET/CT scan
exclusively for the purpose of RTP. This scan may be performed
when a staging PET has already been acquired and the patient is
deemed suitable for radical radiotherapy [37]. This approach
requires two separate PET scans, which has as advantage that it
removes any staging or patient selection issues. However, this
approach is expensive and therefore may not be possible in all
health care systems because of ﬁnancial or logistical limitations.
Another valid approach is to acquire a single PET/CT scan in radio-
therapy treatment position to serve the dual purposes of staging
and TVD. This approach avoids the costs, radiation dose and delay
due to repeated imaging. It requires a complete RTP procedure on
the PET/CT scanner for all potential candidates for radical irradia-
tion despite the fact that a signiﬁcant number of patients will be
classiﬁed with stage IV disease after interpreting the PET images.
It is imperative that the time interval between any imaging used
for the purposes of radiotherapy target volume delineation and
the radiotherapy treatment delivery should be as short as possible.
Several studies examined the effect of radiotherapy ﬁeld changes
size and the effect of staging accuracy with different time scales
from PET/CT scan acquisition [38–41]. All of them demonstrate
that PET/CT scan accuracy reduces with increasing time from the
scan acquisition and that some patients may develop more
advanced stage disease in the time to treatment, which will affect
their chances of long-term survival. Long delays in time to treat-
ment could result in a geographic miss if RT ﬁelds based on prior
PET/CT scans no longer encompass the entire tumor or all involved
lymph node stations. To avoid this issue, it is suggested that radio-
therapy treatment should commence no later than 4 weeks after
acquisition of the PET/CT scan.
Regardless of the selected approach, the PET/CT scanner has to
be equipped with a ﬂat RT table top, RT patient positioning devices
and the CT component has to be calibrated to be safely used for RTP
and RT dose calculation [42].
It is essential that where PET/CT imaging is used for TVD, that
each part of the process has undergone appropriate quality assur-
ance testing and that the entirety of this process has been validated
[43]. This includes patient preparation, scan acquisition, review of
the images acquired, the alignment of the CT and PET components
of the PET/CT scan, transfer of the images to the radiotherapy
planning system and the ﬁnal display of the PET/CT images on
the planning computer.Guidance for PET/CT based visual target volume delineation
The combined procedure consisting of image interpretation,
patient staging, treatment selection, and target volume deﬁnition
requires many different aspects of multidisciplinary clinical exper-
tise. It is recommended that a radiation oncologist (RO) and a
nuclear medicine physician (NMP) / PET radiologist are both
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regarding tumor volume delineation based on PET, emphasis
should be given to the opinion of the NMP / PET physician in
interpretation of the images and to the opinion of the RO in inter-
pretation of all relevant clinical aspects. This also implies that the
use of unmodiﬁed automated delineation of PET images for TVD is
not recommended and that the ﬁnal contour assessment should be
made based on human visual interpretation of the images [24]. To
ensure adequate and reproducible visual interpretation and appli-
cation of PET images for RTP, this procedure should be standard-
ized. The following principles are followed for visual TVD in
using PET/CT imaging in NSCLC patients.General approach of target volume delineation with PET and CT
Target volume deﬁnition involves the identiﬁcation of all
recognizable tumor locations, both the primary tumor and
involved lymph nodes, to delineate a gross target volume (GTV)
as a primary step and secondly the lymph nodes [46].
Depending on the applied strategy, this GTV may also include
the full motion path of all tumor locations to create a respiration
expanded GTV (reGTV). This volume, analogous to a respiration
correlated GTV, contains the tumor at all times of its excursion and
with suitable expansions is capable to form the basis for the
clinical target volume (CTV) and the planning target volume
(PTV) [47,48]. How the combined information in the PET and CT
scans contributes to the generation of a GTV or reGTV depends
on the characteristics of both of the available image sets, as
described here.Where a PET/CT scan is not acquired in the RTP position
Where the PET/CT used for interpretation has not been acquired
in the treatment planning position and is only visually compared
with a 3D radiotherapy planning CT, PET should only be used to
identify those tissues which contain tumor. The RTP CT should be
used when delineating the edge of the GTV and lymph nodes [37].
The radiation oncologist should work together with the nuclear
medicine physician to identify tissues that contain tumor and need
to be included in the GTV.Where a PET/CT scan is acquired in the RTP position, without
respiration compensation
Standard CT for RTP is acquired during free breathing without
speciﬁc measures for compensation of breathing motion, resulting
in deformation and misplacement of tumor locations. In some
cases a general impression of the breathing motion is identiﬁed
using ﬂuoroscopy or slow CT, but these approaches are considered
insufﬁcient for RTP procedures. Since PET is acquired during free
breathing, the images are blurred according to the breathing
motion and provide a good impression of the shape and average
location of tumor sites [49,50]. Therefore, in the most common sce-
nario for RTP, where 3DCT and 3D PET scans are acquired, a reGTV
approach is suggested. In this approach, the tumor should be delin-
eated using the PET to guide both the location and the boundary of
the reGTV. Where suspected disease is located outside the PET
based target volume, for example on CT or based on clinical infor-
mation such as positive biopsy locations, those areas should also be
included in the reGTV [51]. When a margin for the CTV is added to
this reGTV, an internal target volume (ITV) can be generated. Since
PET has a poor resolution of 4–8 mm, it should be noted that 3D
PET/CT may not fully deﬁne the ITV of highly mobile lung tumors
and tumors with low FDG uptake. Hence, in the absence of 4DCT,
the approach of deﬁning a reGTV using PET should be used with
caution in these circumstances [52]. To compensate for under-
estimation of motion in these circumstances, larger expansionmargins from CTV to PTV in the superior and inferior direction
should be considered.
In summary, tumor delineation is a multidisciplinary proce-
dure. The NMP should provide the RO with information about
the shape and location of tumor sites from PET imaging during
delineation of the GTV or reGTV. The RO should use his/her exper-
tise to detect suspicious tissue outside the PET based target volume
and include this in the GTV or reGTV.Where a PET/CT scan is acquired in RTP position, with breathing
compensation
Where adequate respiration compensation is used in the
treatment planning CT, such as with 4DCT, the CT images may
provide reliable information on the shape and location of tumor
sites, except in cases where there is insufﬁcient contrast
between tumor and non-tumor tissues, for example where there
is atelectasis or postobstructive pneumonia (Fig. 1). With 4DCT
acquisition the GTV should be based on the 4DCT, with the
PET being used to discriminate tumor and non-tumor sites to
adapt the GTV where appropriate. It is important that where a
RTP 3D PET/CT scan is registered to a RTP 4DCT scan, the lim-
itations of this registration are appreciated. It is suggested that
PET/CT images should be registered to the average intensity pro-
jection (Ave-IP) scan set using a rigid registration focusing on
bony anatomy which is not affected by respiratory motion
(e.g., spinal column). It is advised that this approach should
not be used routinely for gated treatments.Speciﬁc guidance for PET/CT based TVD
The FDG uptake of the primary tumor and any involved lymph
node(s) may require evaluation with separate FDG-PET ‘‘window/
level (W/L) settings.’’ It is important to standardize these settings,
as variations in W/L settings will result in signiﬁcant differences in
the apparent tumor size on PET images and thus in the resulting
target volumes. In addition, patients may have signiﬁcant varia-
tions in biological factors, such as renal clearance of FDG, resulting
in unpredictable background activity with impact on visual and
quantitative strategies to discriminate tumor from physiological
FDG uptake. There are no validated quantitative approaches for
PET contouring that will result in ideal tumor delineation for all
patients and tumor locations. However, the procedure can be stan-
dardized to some extent using visual calibration of the W/L set-
tings, for example:
s Standardize signal intensity visually according to the biology of
the patient (e.g., always start with a signal brightness of the
liver (Fig. 2), vessels or other normal tissue which is familiar
to the NMP/PET radiologist as normal background physiological
uptake).
s Use a simple linear grayscale (e.g., black to white) for reviewing
the PET images alone. For image fusion of PET with CT use a lin-
ear scale to one or at most two colors (e.g., black to red to yel-
low). Avoid polychromatic scales to avoid misleading color
scaling contours.
Similarly, the W/L settings of CT images will inﬂuence the
tumor delineation procedure. Depending on tumor localization,
the appropriate CT window should be chosen. For example:
s Where the tumor is surrounded by lung tissue, lung window
level settings should be used.
s For delineation of lymph nodes and where tumor invades the
chest wall or mediastinum, soft tissue window settings should
be used.
Fig. 1. Area of atelectasis in the right upper lobe. CT images show insufﬁcient contrast between tumor and non-tumor tissue where atelectasis is present, therefore
delineation should be deﬁned by PET FDG avid areas.
Fig. 2. Example of a standardized signal intensity based on the signal brightness of the liver. The PET signal is very intense in the right lower lobe. When the tumor is
contiguous with a non-tumor structure that has a similar density and where no tumor boundary can be distinguished on CT (e.g., when the tumor is adjacent to the liver), the
reGTV should be deﬁned by the PET FDG avid areas.
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oncologist in selecting standardized PET W/L settings in case of
delineating the reGTV. Variations in W/L settings on PET images
will result in signiﬁcant differences in the apparent tumor size
and thus in the resulting target volumes.Standard delineation procedure for combined PET/CT imaging
When contouring is based on two image sets, discrepancies
between the two scans may lead to uncertainty as where to draw
the ﬁnal contour. It is important to acknowledge these issues and
to standardize solutions, in order to avoid observer variations
and potential geographic miss.
An important question is whether the GTV (or reGTV) may con-
tain areaswhere PET is positive for tumor but CT shows normal lung
tissue. When delineating a reGTV based on PET (e.g., when using
3DCT), all tumor locations should be deﬁned primarily by the FDG
avid signal including their full motion paths, and this may include
areas at the surface where there is no tumor apparent on the non-
respiration correlated CT (Fig. 3). However, when delineating a
GTV based on CT (e.g., when using 4DCT), the primary tumor should
be deﬁned primarily by the structures as seen on CT and therefore
not include air. However, as the PET scan may reveal a so-called‘‘baseline shift’’ i.e., the change of the basic position of the tumor,
in the case of perfect coregistration of bony structures, a clear devia-
tion of the PET signal from the 4DCT created ITV should not be dis-
regarded and might be used to further expand the ITV.
Another common issue is the distinction between tumor and
adjacent soft tissues. In areas where the tumor is contiguous with
a structure that has a similar density and where no tumor bound-
ary can be distinguished on CT (e.g., in the presence of extratho-
racic extensions, see Fig. 4), the reGTV should be deﬁned by the
FDG avid areas [30]. Where the PET scan is compromised by FDG
uptake that is apparently not explained by tumor (e.g., physiologi-
cal uptake in the heart, or active infection), the reGTV should be
deﬁned by the CT images.
For lymph nodes the same approaches for GTV and reGTV can
be applied as for a primary tumor. An additional issue is the iden-
tiﬁcation of the lymph nodes that need to be included in the delin-
eation. A pathological lymph node is deﬁned as a lymph node
which is involved on FDG-PET in the opinion of a trained NMP/
PET radiologist. Non FDG avid (negative) nodes that appear
enlarged on CT and that have a low likelihood of containing macro-
scopic tumor, do not need to be included in the GTV under certain
circumstances [34]. PET negative nodes may be included in the
ﬁnal GTV volume based on information obtained through bron-
choscopy, mediastinoscopy, endoscopic ultrasound sampling
Fig. 3. Example of a delineation of the reGTV based on PET in combination with a 3DCT. A primary tumor can be seen in the left upper lobe with high FDG uptake. The PET
signal shows FDG uptake in air when the modalities are combined which is due to the movement of the tumor.
Fig. 4. Example of a histopathologically proven primary tumor with high FDG uptake in the apical segment of the right upper lobe with a diameter of more than 6 cm, and the
adjacent pleural mass with extrathoracic growth and destruction of the dorsal third to sixth rib on the right. Difﬁculties arise when distinguishing between normal tissue and
tumor in the thoracic wall using CT alone. In this case PET should be used to deﬁne the boundary of the tumor.
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proven lymph node should be included in the GTV. Recently, an
update of guidelines for preoperative mediastinal lymph node
staging is published, recommending EBUS/EUS with ﬁne needle
aspiration as the ﬁrst choice [53]. If EBUS/EUS ﬁndings are negative
and if uncertainty regarding the involvement of mediastinal lymph
nodes remains, video-assisted mediastinoscopy is preferred over
mediastinoscopy as the next most appropriate staging procedure.
It should be noted that patients with lymph nodes measuring
>16 mm on CT and a negative FDG-PET result should undergo med-
iastinoscopy before possible thoracotomy [54]. Combination of
endoscopic staging and surgical staging results in the highest accu-
racy [55]. In addition, clinical considerations may contribute to
identiﬁcation of suspect lymph nodes, e.g., small FDG-negative
lymph nodes that are directly adjacent to the tumor or are located
between other evidently pathological nodes or those which show
progression (tumor growth) as determined from multiple (low
dose) CT scans over a certain period of time.Automated delineation methods for PET/CT imaging
As discussed earlier the one source of error and potential miss
in TVD is the accuracy of delineation of contours by the oncologist
[56]. Given the nature of PET images a number of investigations
have examined the use of automated methods to deﬁne the edge
of the tumor [57,58]. Auto contours may provide consistent con-
tours, but have difﬁculty dealing with normal tissue adjacent to
the tumor with high SUV uptake such as the heart. There is alsono clear consensus on which method most closely approximates
to the tumor position and tumor edge and pathological correlation
has proven difﬁcult [59]. Another difﬁculty with PET based auto-
contouring is the variability of SUV values due to factors other than
tumor activity such as patient biological factors and technical fac-
tors [60]. When delineating a reGTV to include the full motion path
of all tumor locations, the value of auto contours is without any
supporting evidence. Furthermore the information obtained from
the PET component of the scan is complementary to that contained
within the CT scan and the use of information from both may lead
to more successful auto-contouring [49]. Automated PET based
contours can be useful as a starting point for PET based TVD and
are worthy of further investigation, particularly in the era of 4D
PET/CT imaging. At present the IAEA panel recommendation
remains that, outside of a clinical trial context, target volumes gen-
erated with the use of PET should be delineated using visual inter-
pretation alone or should be visually edited following any
automated target volume delineation [24].The use of PET to deﬁne a respiration expanded GTV for mobile
lung tumors
As PET images are acquired over a number of minutes at each
table position, it has been suggested that PET could deﬁne the
entire motion trajectory of a lung tumor. Tumors identiﬁed as
low risk of macroscopic disease extension (MDE) show lower rates
of disease around the GTV than do high-risk tumors. Both PET and
CT accurately visualize the CTV(path) in low-risk tumors, but
32 PET/CT for target volume delineation in NSCLC: IAEA consensus report 2014underestimate MDE in high-risk tumors [59]. When a suitable mar-
gin is added for microscopic extensions of a moving lung tumor,
this volume is also known as the internal target volume (ITV).
According to ICRU 62, the ITV is deﬁned as the ‘‘internal margin’’
plus a CTV expansion [47]. Phantom studies have demonstrated
that the PET target volume may contain all of the respiratory
motion (respiration expanded GTV) of a moving lung tumor
[50,61]. Hence, in the absence of other respiration motion com-
pensation techniques (e.g., respiratory gating or real-time track-
ing), PET based target volumes may be used to approach a PET
based ITV approach, namely the respiration expanded GTV.
Unfortunately clinical investigations using 3D PET/CT imaging
have not shown consistently that a PET based ITV is identical to
a 4DCT based ITV for small tumors [52]. A recent study using 4D
PET/CT imaging has demonstrated that a 4D PET based ITV closely
approximates to a 4DCT [62]. Using 4D PET/CT imaging may lead to
better quantiﬁcation of tumor motion during prolonged radiother-
apy treatment times but further investigation and clinical
validation are required.Four dimensional PET/CT imaging
With a 4D PET/CT the 4DCT and 4D PET scan are retrospectively
binned into a number of respiratory phases correlated with the
breathing cycle using a respiratory tracking system. Each phase
of the 4D PET is corrected for attenuation with the respective phase
of the 4DCT. 4D PET/CT imaging may overcome some of the inac-
curacies associated with a free breathing PET/CT scan. One such
factor is tumor motion. In 3D PET/CT imaging, the CT component
is acquired as fast CT which may catch a mobile lung tumor at
an extreme of the ITV or cause artefacts, while PET scans are
acquired over a number of minutes. Hence the SUV for a given
pixel is an average of the SUV over that time period.
Furthermore, in integrated PET/CT acquisition the attenuation cor-
rection is based on the CT data and as mentioned above this may
misrepresent the average density for a given pixel position.
Hence, in essence, for mobile lung tumors the PET component is
more akin to 4D imaging while the CT component is more akin
to a 3D imaging technique. A number of studies have shown size-
able differences in SUV calculation between 3D PET/CT and 4D PET/
CT imaging [63,64]. Using 4D PET/CT imaging may provide more
accurate SUV quantiﬁcation for moving lung cancer and has impli-
cations for auto-contouring which may lead to newmethods of PET
based TVD.CTV and PTV expansions to a PET derived GTV
These guidelines have focused on the delineation of standard-
ized GTV or reGTV contours. Subsequently, these volumes need
to be expanded to a CTV and to a PTV. The CTV expansion is based
on pathological tumor characteristics, and therefore not dependent
on the imaging technique or GTV delineation strategy. Clinically
applied expansions from the GTV to CTV are generally in the range
of 5–8 mm [65]. The PTV expansion can be calculated in a proba-
bilistic approach by considering all systematic uncertainties, all
random uncertainties and also the width of treatment beam
penumbra [66]. This may also include patient characteristics such
as breathing motion, if this has not already been incorporated in
the GTV deﬁnition. A more basic approach can be used when a
PET based respiration expanded GTV has been created, and the
PTV expansion is applied to compensate for setup variations alone
(e.g., 1 cm in all directions). When a GTV based on 4DCT has been
created, PTV expansions are primarily based on the characteristics
derived from CT and other systematic errors (e.g., errors fromimage fusion and target volume delineation) of which all can be
taken into account with the van Herk formula [66].
PET combined with MR imaging
When envisioning the future, it is interesting to follow the
recent advances in hybrid imaging systems which made it possible
to combine PET and (functional) MR information. With the
combination of functional MR and PET information new possibili-
ties in functional cancer imaging are emerging [67]. However,
one of the ﬁrst few studies reported no signiﬁcant difference in
diagnostic performance when PET/MR was compared to PET/CT
[68,69]. Interestingly, a recent study showed that PET/MR imaging
could have an advantage in lymph node detection [70]. No study
yet exists about the use of PET/MR in tumor volume delineation
but further research is awaited.
Conclusions
It remains the recommendation of an IAEA expert panel that an
appropriately timed and technically adequate PET/CT imaging is an
essential component in the radiotherapy treatment planning pro-
cess for lung cancer. Speciﬁc guidance regarding the interpretation
of PET/CT imaging for TVD is provided. It is also recognized that
further research is needed in the ﬁelds of 4D PET/CT imaging and
automated TVD techniques.
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